BACKGROUND: Human rhinovirus (HRV) is the most frequent virus associated with COPD exacerbations. Viral infections increase exacerbation severity and likelihood of hospitalization. As ease of sampling blood makes serum a more practical marker than sputum, we investigated whether changes in serum interferon-gamma-inducible protein 10 (IP-10) from baseline to exacerbation were higher in airway HRV-positive exacerbations and whether IP-10 levels related to HRV load. METHODS: One hundred thirty-six patients with COPD and 70 controls were included over 2 years and 72 exacerbations sampled. HRV positivity and load were determined by reverse transcriptase-polymerase chain reaction in nasopharyngeal swabs and/or sputum at baseline and exacerbation. IP-10 was measured by enzyme-linked immunosorbent assay in serum and compared with HRV load. RESULTS: At baseline, serum IP-10 was higher in patients with COPD than controls; medians were 149.4 pg/mL (103-215) and 111.7 pg/mL (82-178), P = .02. The presence of HRV at baseline did not increase IP-10: patients with COPD, 166.9 pg/mL (110-240) and 149.4 pg/mL (103-215), P = .30; controls, 136.4 pg/mL (77-204) and 111.7 pg/mL (82-178), P = .53. IP-10 increased significantly from baseline to exacerbation in HRV-positive exacerbations: 154.9 pg/mL (114.0-195.1) to 207.5 pg/mL (142.1-333.5), P = .009. There was no change in IP-10 between baseline and exacerbation in HRV-negative exacerbations: 168.3 pg/mL (94.3-249.8) and 175.6 pg/mL (107.2-290.4), P = .49. At exacerbation, IP-10 correlated with sputum viral load: rho = 0.48; P = .02. In receiver operating characteristics analysis, the combination of IP-10 and coryzal symptoms gave an area under the curve of 0.82 (95% CI, 0.74-0.90). CONCLUSIONS: IP-10 increases from baseline to exacerbation in HRV-positive exacerbations and correlates with sputum HRV load. Serum IP-10 may be useful as a novel marker for these events.
BACKGROUND:Human rhinovirus (HRV) is the most frequent virus associated with COPD exacerbations. Viral infections increase exacerbation severity and likelihood of hospitalization. As ease of sampling blood makes serum a more practical marker than sputum, we investigated whether changes in serum interferon-gamma-inducible protein 10 (IP-10) from baseline to exacerbation were higher in airway HRV-positive exacerbations and whether IP-10 levels related to HRV load. METHODS: One hundred thirty-six patients with COPD and 70 controls were included over 2 years and 72 exacerbations sampled. HRV positivity and load were determined by reverse transcriptase-polymerase chain reaction in nasopharyngeal swabs and/or sputum at baseline and exacerbation. IP-10 was measured by enzyme-linked immunosorbent assay in serum and compared with HRV load. RESULTS: At baseline, serum IP-10 was higher in patients with COPD than controls; medians were 149.4 pg/mL (103-215) and 111.7 pg/mL (82-178), P = .02. The presence of HRV at baseline did not increase IP-10: patients with COPD, 166.9 pg/mL (110-240) and 149.4 pg/mL (103-215), P = .30; controls, 136.4 pg/mL (77-204) and 111.7 pg/mL (82-178), P = .53. IP-10 increased significantly from baseline to exacerbation in HRV-positive exacerbations: 154.9 pg/mL (114.0-195.1) to 207.5 pg/mL (142.1-333.5), P = .009. There was no change in IP-10 between baseline and exacerbation in HRV-negative exacerbations: 168.3 pg/mL (94.3-249.8) and 175.6 pg/mL (107.2-290.4), P = .49. At exacerbation, IP-10 correlated with sputum viral load: rho = 0.48; P = .02. In receiver operating characteristics analysis, the combination of IP-10 and coryzal symptoms gave an area under the curve of 0.82 (95% CI, 0.74-0.90). CONCLUSIONS:IP-10 increases from baseline to exacerbation in HRV-positive exacerbations and correlates with sputum HRV load. Serum IP-10 may be useful as a novel marker for these events.
Authors: T A Seemungal; G C Donaldson; E A Paul; J C Bestall; D J Jeffries; J A Wedzicha Journal: Am J Respir Crit Care Med Date: 1998-05 Impact factor: 21.405
Authors: Daniel C Pevear; Frederick G Hayden; Tina M Demenczuk; Linda R Barone; Mark A McKinlay; Marc S Collett Journal: Antimicrob Agents Chemother Date: 2005-11 Impact factor: 5.191
Authors: A Sauty; M Dziejman; R A Taha; A S Iarossi; K Neote; E A Garcia-Zepeda; Q Hamid; A D Luster Journal: J Immunol Date: 1999-03-15 Impact factor: 5.422
Authors: Jason C L Spurrell; Shahina Wiehler; Raza S Zaheer; Scherer P Sanders; David Proud Journal: Am J Physiol Lung Cell Mol Physiol Date: 2005-03-11 Impact factor: 5.464
Authors: Elizabeth L Hardaker; Alicia M Bacon; Karey Carlson; Amy K Roshak; James J Foley; Dulcie B Schmidt; Peter T Buckley; Meghan Comegys; Reynold A Panettieri; Henry M Sarau; Kristen E Belmonte Journal: FASEB J Date: 2003-11-03 Impact factor: 5.191
Authors: Sandra Grumelli; David B Corry; Li-Zhen Song; Ling Song; Linda Green; Joseph Huh; Joan Hacken; Rafael Espada; Remzi Bag; Dorothy E Lewis; Farrah Kheradmand Journal: PLoS Med Date: 2004-10-19 Impact factor: 11.069
Authors: Kaharu C Sumino; Michael J Walter; Cassandra L Mikols; Samantha A Thompson; Monique Gaudreault-Keener; Max Q Arens; Eugene Agapov; David Hormozdi; Anne M Gaynor; Michael J Holtzman; Gregory A Storch Journal: Thorax Date: 2010-07 Impact factor: 9.139
Authors: A Casrouge; A Bisiaux; L Stephen; M Schmolz; J Mapes; C Pfister; S Pol; V Mallet; M L Albert Journal: Clin Exp Immunol Date: 2012-01 Impact factor: 4.330
Authors: Qun Wu; Di Jiang; Niccolette R Schaefer; Laura Harmacek; Brian P O'Connor; Thomas E Eling; Oliver Eickelberg; Hong Wei Chu Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-11-30 Impact factor: 5.464